ReviewCardiovascular diagnosis and therapy2020
Pulmonary hypertension in low- and middle-income countries with focus on sub-Saharan Africa.
Review in Cardiovascular diagnosis and therapy, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 34 citations in OpenAlex.
- Trends and future projections of the disease burden of pulmonary arterial Hypertension-related heart failure in China and G20 countries: Based on the global burden of disease 2023 database.International journal of cardiology. Cardiovascular risk and prevention · 2026Article
- Clinical profile, survival outcomes, and predictors of mortality in neonates with persistent pulmonary hypertension: a follow-up study from Hawassa, Ethiopia.BMC pediatrics · 2026Article
- Clinical characteristics, management strategies, and survival outcomes of patients with chronic thromboembolic pulmonary hypertension in Central Asia: experience from the sole pulmonary endarterectomy center.Frontiers in cardiovascular medicine · 2026Article
- Geographic Variations, Peculiarities, and Management of Heart Failure in Sub-Saharan Africa.Current heart failure reports · 2025Review
- Pathways to Diagnose Infectious Pulmonary Vascular Disease in Rural Mozambique.Infectious disease reports · 2025Article
- Technical Challenges in Studying Infectious Disease-Associated Pulmonary Hypertension in Low- and Middle-Income Countries with Limited Resources.Infectious disease reports · 2025Review
- Global pulmonary arterial hypertension trends and projections to 2046: a multi-method analysis of epidemiologic and demographic drivers using GBD 2021.Journal of thoracic disease · 2025Article
- Genetic evidence for the causal effect of clonal hematopoiesis on pulmonary arterial hypertension.BMC cardiovascular disorders · 2025Article
- Exploring the patient perspective in pulmonary hypertension.The European respiratory journal · 2024Article
- Diagnosis and Treatment Patterns of Chronic Thromboembolic Pulmonary Hypertension in Russia, Kazakhstan, Turkey, Lebanon, and Saudi Arabia: A Registry Study.Drugs - real world outcomes · 2024Article
- Article
- Prevalence of pulmonary hypertension and its associated factors among chronic obstructive pulmonary diseases patients at public hospitals of Addis Ababa, Ethiopia, 2024: a facility-based cross-sectional study.Frontiers in public health · 2024Article
- Article
- HIV status and survival of patients with pulmonary hypertension due to left heart disease: the Pan African Pulmonary Hypertension Cohort.Scientific reports · 2023Article
- Pulmonary hypertension in remote and disadvantaged population: overcoming unique challenges for improved outcomes.Internal medicine journal · 2023Review
- Parasitic lung diseases.European respiratory review : an official journal of the European Respiratory Society · 2022Review
- Long-Term Follow-up of Human Immunodeficiency Virus-Associated Pulmonary Hypertension: Clinical Features and Survival Outcomes of the Pan Africa Pulmonary Hypertension Cohort (PAPUCO).Open forum infectious diseases · 2022Article
- Pulmonary hypertension in developing countries: Limiting factors in time to diagnosis, specialised medications and contextualised recommendations.African journal of thoracic and critical care medicine · 2022Review
- Pulmonary hypertension among patients hospitalized with acute heart failure in Buea, South West Region of Cameroon.The Pan African medical journal · 2022Article
- Evaluating of Red Blood Cell Distribution Width, Comorbidities and Electrocardiographic Ratios as Predictors of Prognosis in Patients with Pulmonary Hypertension.Diagnostics (Basel, Switzerland) · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 7 institutions in 5 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pulmonary hypertension (PH) is a devastating, progressive disease with increasingly debilitating symptoms and usually shortened overall life expectancy. This article reviews the global epidemiology of PH with focus on low- and middle-income countries (LMICs) and sub-Sahara African in particular. Although left ventricular heart disease is the most common cause globally, the main contributing risk factors in LMICs are chronic infectious diseases especially human immunodeficiency virus (HIV) and schistosomiasis. Other important risk factors of PH are rheumatic heart disease, untreated congenital heart disease (CHD), and sickle cell disease. Despite existing epidemiological data of PH risk factors suggesting a high prevalence in sub-Saharan Africa (SSA), the available literature is limited. International registries in LMICs like the pan African pulmonary hypertension cohort (PAPUCO) study are essential to provide information about the causes, treatment, outcome, and the natural course of PH in Africa and other parts of the world. In addition, there is a need to track diagnostic and management practices in order to develop suitable algorithms to diagnose PH in LMICs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.